Get the Stockscreener App
27.35
4.28%
1.122
Maze Therapeutics Inc stock is traded at $27.35, with a volume of 263.10K.
It is up +4.28% in the last 24 hours and up +12.88% over the past month.
Maze Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small-molecule precision medicines for patients living with renal, cardiovascular, and related metabolic, or CVRM, diseases, including obesity. The company is advancing a pipeline using its Compass platform, which allows the company to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process it refers to as variant functionalization. It is currently advancing two programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach for chronic kidney disease, or CKD.
See More
Previous Close:
$26.23
Open:
$26.59
24h Volume:
263.10K
Relative Volume:
0.34
Market Cap:
$1.52B
Revenue:
$2.50M
Net Income/Loss:
$-131.12M
P/E Ratio:
-9.6205
EPS:
-2.8431
Net Cash Flow:
$-112.73M
1W Performance:
+5.69%
1M Performance:
+12.88%
6M Performance:
+1.87%
1Y Performance:
-6.52%
1-Day Range:
$26.46
$28.11
1-Week Range:
$25.88
$29.32
52-Week Range:
$21.95
$53.65
Maze Therapeutics Inc Stock (MAZE) Company Profile
Name
Maze Therapeutics Inc
Sector
Industry
Phone
(650) 850-5070
Address
171 OYSTER POINT BOULEVARD, SUITE 300, SOUTH SAN FRANCISCO
Compare MAZE vs VRTX, MRNA, REGN, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MAZE
Maze Therapeutics Inc
|
27.35 | 1.52B | 2.50M | -131.12M | -112.73M | -2.8431 |
VRTX
Vertex Pharmaceuticals Inc
|
509.72 | 129.19B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
237.78 | 94.93B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
801.11 | 82.48B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
848.35 | 53.35B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
371.37 | 42.01B | 5.76B | 514.49M | 1.10B | 4.4813 |
Maze Therapeutics Inc Stock (MAZE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-23-26 | Initiated | Citigroup | Buy |
| Mar-18-26 | Initiated | Truist | Buy |
| Mar-10-26 | Initiated | Mizuho | Outperform |
| Dec-04-25 | Initiated | Wells Fargo | Overweight |
| Nov-14-25 | Initiated | Raymond James | Outperform |
| Sep-02-25 | Initiated | BTIG Research | Buy |
| Jul-23-25 | Initiated | H.C. Wainwright | Buy |
| Jul-08-25 | Initiated | Wedbush | Outperform |
View All
Maze Therapeutics Inc Stock (MAZE) Latest News
Maze Therapeutics (NasdaqGM:MAZE) Stock Price - Simply Wall Street
Two trusts sold 31,908 and 2,593 shares under Maze Therapeutics (MAZE) CEO Jason V. Coloma’s trading plan. - Stock Titan
After exercising options, Harold Bernstein sold 16,141 Maze Therapeutics (MAZE) shares. - Stock Titan
An officer plans to sell 16,141 Maze Therapeutics (MAZE) shares on October 1, 2026. - Stock Titan
7,500 shares sold under a trading plan at Maze Therapeutics (MAZE) after an option exercise. - Stock Titan
An officer proposes selling 34,501 shares held by two trusts at Maze Therapeutics (Nasdaq: MAZE). - Stock Titan
Maze Therapeutics (Nasdaq:MAZE)Stock Analysis - Simply Wall Street
Maze Therapeutics Chief Medical Officer Dumps Entire Direct Stake in the Company for $255,000 - The Motley Fool
Maze Therapeutics Chief Medical Officer Dumps Entire Direct Stake in the Company for $255,000 - Yahoo Finance
Maze Therapeutics Chief Medical Officer Dumps Entire Direct Stake in the Company for $255,000 - The Globe and Mail
Maze Therapeutics at Citi summit: early data, bigger tests ahead By Investing.com - Investing.com South Africa
Maze Therapeutics at Citi summit: early data, bigger tests ahead By Investing.com - Investing.com Canada
Maze therapeutics president, R&D & CMO, sells $254,501 in shares By Investing.com - Investing.com Australia
Maze Therapeutics at Wells Fargo conference: pipeline gains pace By Investing.com - Investing.com Nigeria
Maze Therapeutics at Wells Fargo conference: pipeline gains pace By Investing.com - Investing.com South Africa
Maze Therapeutics at Wells Fargo conference: pipeline gains pace By Investing.com - Investing.com India
Maze Therapeutics at Wells Fargo conference: pipeline gains pace By Investing.com - Investing.com Canada
Maze Therapeutics at Wells Fargo conference: pipeline gains pace By Investing.com - Investing.com UK
Maze Therapeutics (MAZE) Institutional Ownership 2026 - MarketBeat
Maze therapeutics president, R&D & CMO, sells $254,501 in shares - Investing.com
Maze therapeutics president, R&D & CMO, sells $254,501 in shares By Investing.com - Investing.com Nigeria
Maze therapeutics president, R&D & CMO, sells $254,501 in shares By Investing.com - Investing.com India
Maze therapeutics president, R&D & CMO, sells $254,501 in shares By Investing.com - Investing.com Canada
Maze therapeutics president, R&D & CMO, sells $254,501 in shares By Investing.com - Investing.com UK
Maze therapeutics president, R&D & CMO, sells $254,501 in shares - Investing.com
Maze Therapeutics (MAZE) R&D chief exits direct stake - Stock Titan
Maze Therapeutics CEO Coloma Jason V Offloads 22,638 Shares at $25.77 to $27.12 Each - Kalkine Media
Don't Ignore The Insider Selling In Maze Therapeutics - simplywall.st
Don't Ignore The Insider Selling In Maze Therapeutics - simplywall.st
MAZE News | MAZE THERAPEUTICS INC (NASDAQ:MAZE) - ChartMill
Maze Therapeutics CSBO Atul Dandekar Sells 6,434 Shares to Cover RSU Tax Withholding - Kalkine Media
Maze Therapeutics (NASDAQ: MAZE) officer lines up new stock sale after recent 10b5-1 trades - stocktitan.net
Maze Therapeutics Chief Executive Officer Sold Shares Worth Over $593K - TradingView
Maze Therapeutics (MAZE) legal chief sells stock for taxes - stocktitan.net
Insider at Maze Therapeutics (MAZE) sells shares to cover taxes - stocktitan.net
Maze Therapeutics (MAZE) CEO sells shares to cover taxes - stocktitan.net
Maze Therapeutics (MAZE) R&D chief sells shares to cover RSU taxes - stocktitan.net
Courtney Phillips Executes 11,000 Zero-Cost Options in Maze Therapeutics (NASDAQ: MAZE) on September 1, 2026 - Kalkine Media
Maze Therapeutics Officer Courtney Phillips Reports RSU Vesting and Stock Settlement - Kalkine Media
Maze Therapeutics CEO Jason V Coloma Reports RSU Vesting and Trust Share Sales in Form 4 Filing - Kalkine Media
RSU vesting gives Maze Therapeutics (MAZE) exec 12,500 shares - stocktitan.net
Maze Therapeutics (MAZE) CEO gets 50K shares, trims stake via trust sales - Stock Titan
Rule-based stock plan leads Maze Therapeutics (MAZE) exec to sell shares and log 20,000 RSUs - stocktitan.net
Maze Therapeutics (MAZE) legal chief gets 11,000 shares - stocktitan.net
Officer plans to sell up to $623K in Maze Therapeutics (MAZE) stock from vested RSUs - Stock Titan
Maze Therapeutics to Participate in Three Upcoming Investor Conferences - markets.businessinsider.com
Maze Therapeutics to Participate in Three Upcoming Investor Conferences - finance.yahoo.com
Maze Therapeutics (MAZE) executive plans new stock sale after recent trades - Stock Titan
MindMaze Therapeutics to Present at Upcoming Investor and Industry Conferences - finance.yahoo.com
Maze Therapeutics CSBO Dandekar divests $206,823 of common stock - Investing.com India
Maze Therapeutics Inc Stock (MAZE) Financials Data
Revenue
Net Income
Cash Flow
EPS
Maze Therapeutics Inc Stock (MAZE) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Coloma Jason V | Officer |
Oct 01 '26 |
Proposed Sale |
27.05 |
34,501 |
933,252 |
0 |
| Bernstein Harold | President, R&D & CMO |
Oct 01 '26 |
Option Exercise |
10.42 |
16,141 |
168,189 |
16,141 |
| Bernstein Harold | President, R&D & CMO |
Oct 01 '26 |
Sale |
26.93 |
16,141 |
434,743 |
0 |
| HAROLD BERNSTEIN | Officer |
Oct 01 '26 |
Proposed Sale |
27.18 |
16,141 |
438,712 |
0 |
| Dandekar Atul | CSBO |
Sep 29 '26 |
Option Exercise |
10.42 |
7,500 |
78,150 |
39,816 |
| Dandekar Atul | CSBO |
Sep 29 '26 |
Sale |
27.06 |
7,500 |
202,921 |
32,316 |
| Bernstein Harold | President, R&D & CMO |
Sep 04 '26 |
Sale |
26.22 |
9,705 |
254,502 |
0 |
| HAROLD BERNSTEIN | Officer |
Sep 04 '26 |
Proposed Sale |
25.87 |
9,705 |
251,068 |
0 |
| Bernstein Harold | President, R&D & CMO |
Sep 03 '26 |
Sale |
26.01 |
5,189 |
134,969 |
9,705 |
| Dandekar Atul | CSBO |
Sep 03 '26 |
Sale |
26.01 |
3,243 |
84,354 |
32,316 |
3.46%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):